Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours

European Journal of Cancer Care

Volumn 19, Issue 5, 2010, Pages 648-655

  Lopez Pousa A ^a   Rifa J ^b   casas de tejerina, A ^c   Gonzalez Larriba J L ^d   Iglesias, C ^e   Gasquet, J A ^f   Carrato, A ^g  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e Salutis Research SL   (Spain)

^f Amgen SA   (Spain)

^g Elche University Hospital   (Spain)

Author keywords

Neutropenia; Predictive model; Solid tumours

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG EFFECT; EPIDEMIOLOGY; FEMALE; HUMAN; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; NEUTROPENIA; NEUTROPHIL; PROSPECTIVE STUDY; SEX DIFFERENCE; SPAIN; THEORETICAL MODEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MODELS, THEORETICAL; NEOPLASMS; NEUTROPENIA; NEUTROPHILS; PROSPECTIVE STUDIES; SEX FACTORS; SPAIN; YOUNG ADULT;

EID: 77955726371     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2009.01121.x     Document Type: Article

References (30)

1. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. European Journal of Cancer 2006, 42:2433-2453.
2. Aslani A, Smith RC, Allen BJ, Pavlakis N, Levi JA. The predictive value of body protein for chemotherapy-induced toxicity. Cancer 2000, 88:796-803.
3. Blay JY, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset C, Freyer G, Philip T, Biron P. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. Journal of Clinical Oncology 1996, 14:636-643.
4. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. The New England Journal of Medicine 1995, 332:901-906.
5. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005, 103:1916-1924.
6. Chrischilles EA, Link BK, Scott SD, Delgado DJ, Fridman M. Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin's lymphoma. Cancer Control 2003, 10:396-403.
7. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004, 100:228-237.
8. Dixon DO, Neilan B, Jones SE, Lipschitz DA, Miller TP, Grozea PN, Wilson HE. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. Journal of Clinical Oncology 1986, 4:295-305.
9. Fazio MT, Glaspy JA. The impact of granulocyte colony-stimulating factor on quality of life in patients with severe chronic neutropenia. Oncology Nursing Forum 1991, 18:1411-1414.
10. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Diseases 2002, 34:730-751.
11. Intragumtornchai T, Sutheesophon J, Sutcharitchan P, Swasdikul D. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leukemia and Lymphoma 2000, 37:351-360.
12. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcolt J. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. Journal of Clinical Oncology 2000, 18:3038-3051.
13. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006, 106:2258-2266.
14. Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. Journal of Clinical Oncology 1990, 8:963-977.
15. Lepage E, Gisselbrecht C, Haioun C, Sebban C, Tilly H, Bosly A, Morel P, Herbrecht R, Reyes F, Coiffier B. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte). Annals of Oncology 1993, 4:651-656.
16. Lyman GH. A predictive model for neutropenia associated with cancer chemotherapy. Pharmacotherapy 2000, 20(7):104S-111S. pt 2
17. Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003, 98:2402-2409.
18. Lyman GH, Kuderer N, Agboola O, Balducci L. Evidence-based use of colony-stimulating factors in elderly cancer patients. Cancer Control 2003, 10:487-499.
19. Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005, 10:427-437.
20. Padilla G, Ropka ME. Quality of life and chemotherapy-induced neutropenia. Cancer Nursing 2005, 28:167-171.
21. Pizzo PA, Hathorn JW, Hiemenz J. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. The New England Journal of Medicine 1986, 315:552-558.
22. Ray-Coquard I, Borg C, Bachelot T, Sebban C, Philip I, Clapisson G, Le Cesne A, Biron P, Chauvin F, Blay JY. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. British Journal of Cancer 2003, 88:181-186. ELYPSE Study Group
23. Rivera E, Erder MH, Fridman M, Frye D, Hortobagyi GN. First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study. Breast Cancer Research 2003, 5:R114-R120.
24. Savvides P, Terrin N, Erban J, Selker HP. Development and validation of a patient-specific predictive instrument for the need for dose reduction in chemotherapy for breast cancer: a potential decision aid for the use of myeloid growth factors. Supportive Care in Cancer 2003, 11:313-320.
25. Schimpff SC, Gaya H, Klastersky J, Tattersall MH, Zinner SH. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group. Journal of Infectious Diseases 1978, 137:14-29.
26. Silber JH, Fridman M, DiPaola RS, Erder MH, Pauly MV, Fox KR. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. Journal of Clinical Oncology 1998, 16:2392-2400.
27. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. Journal of Clinical Oncology 2006, 24:3187-3205.
28. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. Journal of Clinical Oncology 1992, 10:316-322.
29. Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. Journal of Clinical Oncology 2005, 23:1178-1184.
30. Voog E, Bienvenu J, Warzocha K, Moullet I, Dumontet C, Thieblemont C, Monneret G, Gutowski M-C, Coiffier B, Salles G. Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor system. Journal of Clinical Oncology 2000, 18:325-331.